JP2009500397A5 - - Google Patents

Download PDF

Info

Publication number
JP2009500397A5
JP2009500397A5 JP2008520118A JP2008520118A JP2009500397A5 JP 2009500397 A5 JP2009500397 A5 JP 2009500397A5 JP 2008520118 A JP2008520118 A JP 2008520118A JP 2008520118 A JP2008520118 A JP 2008520118A JP 2009500397 A5 JP2009500397 A5 JP 2009500397A5
Authority
JP
Japan
Prior art keywords
preparation
transdermal
subject
epinastine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2008520118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2006/314005 external-priority patent/WO2007007851A1/en
Publication of JP2009500397A publication Critical patent/JP2009500397A/ja
Publication of JP2009500397A5 publication Critical patent/JP2009500397A5/ja
Abandoned legal-status Critical Current

Links

JP2008520118A 2005-07-08 2006-07-07 エピナスチンを含む眼科用経皮吸収型製剤 Abandoned JP2009500397A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69736905P 2005-07-08 2005-07-08
PCT/JP2006/314005 WO2007007851A1 (en) 2005-07-08 2006-07-07 Percutaneously absorptive ophthalmic preparation comprising epinastine

Publications (2)

Publication Number Publication Date
JP2009500397A JP2009500397A (ja) 2009-01-08
JP2009500397A5 true JP2009500397A5 (enExample) 2009-08-20

Family

ID=37016261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008520118A Abandoned JP2009500397A (ja) 2005-07-08 2006-07-07 エピナスチンを含む眼科用経皮吸収型製剤

Country Status (6)

Country Link
US (1) US20090143359A1 (enExample)
EP (1) EP1901724A1 (enExample)
JP (1) JP2009500397A (enExample)
KR (1) KR20080034916A (enExample)
CN (1) CN101217948A (enExample)
WO (1) WO2007007851A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090042956A (ko) * 2006-08-28 2009-05-04 센주 세이야꾸 가부시키가이샤 안과 경피 흡수형 제제
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
JP5693026B2 (ja) * 2010-03-12 2015-04-01 株式会社フジモト・コーポレーション セレギリン含有貼付製剤
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
JP7114668B2 (ja) * 2020-10-08 2022-08-08 参天製薬株式会社 エピナスチン又はその塩を含有する花粉破裂抑制剤
CN116669705A (zh) * 2020-12-24 2023-08-29 参天制药株式会社 含有依匹斯汀或其盐的涂布施予用医药组合物
EP4268825A4 (en) * 2020-12-24 2024-12-11 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION CONTAINING EPINASTIN OR SALT THEREOF WITH SULPHUR-BASED ANTIOXIDANT
WO2022138826A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩を含有する塗布投与用医薬組成物
WO2025205960A1 (ja) * 2024-03-27 2025-10-02 参天製薬株式会社 エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
RU2125427C1 (ru) * 1998-05-27 1999-01-27 Миронова Эмилия Михайловна Средство для лечения глазных заболеваний - оковидит
TWI233810B (en) * 1999-02-19 2005-06-11 Hisamitsu Pharmaceutical Co A paster sheet
WO2001026648A1 (en) * 1999-10-13 2001-04-19 Senju Pharmaceutical Co., Ltd. Ophthalmic adhesive preparations for percutaneous absorption
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
DE10060852A1 (de) * 2000-12-06 2002-06-20 Hexal Ag Absorptionsmittel und Kanalbildner enthaltende wirkstoffundurchlässige Deckschicht oder abziehbare Schutzschicht eines transdermalen therapeutischen Systems
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
EP1591110B1 (en) * 2003-01-22 2015-03-18 Senju Pharmaceutical Co., Ltd. Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
JP5315051B2 (ja) * 2005-07-08 2013-10-16 千寿製薬株式会社 オロパタジンを含む眼科用経皮吸収型製剤

Similar Documents

Publication Publication Date Title
JP2011516477A5 (enExample)
JP2010502564A5 (enExample)
JP2011520805A5 (enExample)
JP2009501797A5 (enExample)
JP2022008403A5 (enExample)
JP2009535162A5 (enExample)
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
IL208982B (en) A preparation containing baclofen or a salt, derivative or delayed release formulation thereof for use in the treatment of Alzheimer's disease
BRPI0818621A8 (pt) composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
BRPI0608152A2 (pt) formulações para tratamento ocular
JP2009500397A5 (enExample)
BRPI0818623A2 (pt) composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
JP2011510014A5 (enExample)
TW200736252A (en) Novel heteroaryl substituted benzothiazoles
JP2010222367A5 (enExample)
JP2009500398A5 (enExample)
EP2156833A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR EYES DISEASE WITH SELF-SELECTIVE NON-ERGOT D2 RECEPTOR AGONIST AS AN ACTIVE SUBSTANCE
JP2015025011A5 (enExample)
JP2012523430A5 (enExample)
JP2013534527A5 (enExample)
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
ME02608B (me) Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
HRP20241509T1 (hr) Pripravak za oči koji sadrži bromfenak s povećanom bioraspoloživošću
WO2013184650A3 (en) Treatment of ocular inflammatory diseases using laquinimod